Summary Variants may cause few breakthrough infections in vaccinated Researchers find no evidence of widespread virus escape Past infection with B117/Alpha confers broad protection June 22 – COVID-19 vaccines made by AstraZeneca (AZN.L) and the Pfizer-BioNTech (PFE.N), (22UAy.DE) alliance remain broadly effective against Delta and Kappa variants of the COVID-19 causing virus, which […]
Anglo-Swedish drugmaker AstraZeneca (AZN.L) said on Tuesday a study of its monoclonal antibody treatment, AZD7442, did not meet the main goal of preventing symptomatic COVID-19 in people recently exposed to the novel coronavirus. The company said the participants in the trial were unvaccinated adults older than 18 years with confirmed […]
LONDON — AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among all adults in a long-anticipated U.S. study, raising hopes that the findings could help rebuild public confidence in the beleaguered shot in other countries and moving a step closer to clearance for American use. AstraZeneca […]
MUMBAI – The Serum Institute of India (SII) expects WHO emergency use authorization soon for the Oxford University/AstraZeneca coronavirus vaccine, which it is producing for mid and low income countries, its chief executive said. The World Health Organization (WHO) listed Pfizer and BioNTech’s COVID-19 shot for emergency use […]
LONDON – One of the world’s leading COVID-19 experimental vaccines produces a immune response in both young and old adults, raising hopes of a path out of the gloom and economic destruction wrought by the novel coronavirus. The vaccine, developed by the University of Oxford, also triggers lower […]
Founder Editor
